Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 9/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1479104 | 0.84 | GPR35 (0.59) | GPR35ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL590156 | 0.84 | GPR35 (0.59) | GPR35ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL69964 | 0.84 | GPR35 (0.59) | GPR35ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL29262876 | 0.84 | GPR35 (0.63) | GPR35ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL11211745 | 0.84 | GPR35 (0.52) | GPR35ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL9112380 | 0.82 | GPR35 (0.83) | GPR35ALDH1A1KDM4EMEN1MAPT | |
| Ammonia Solution, Strong SCHEMBL11020682 | 0.82 | GPR35 (0.57) | GPR35ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL9500870 | 0.82 | GPR35 (0.68) | GPR35ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL9724485 | 0.82 | GPR35 (0.57) | GPR35ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL9328126 | 0.82 | GPR35 (0.57) | GPR35ALDH1A1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112320766-B | Preparation method and application of hollow mesoporous inorganic oxide nanosphere solid alkali | 西南大学 | 2023-10-27 | — | — | CN | claimed |
| CN-112320766-A | Preparation method and application of hollow mesoporous inorganic oxide nanosphere solid base | 西南大学 | 2021-02-05 | — | — | CN | claimed |
| CN-112320766-B | Preparation method and application of hollow mesoporous inorganic oxide nanosphere solid alkali | 西南大学 | 2023-10-27 | — | — | CN | disclosed |
| US-11292929-B2 | UV curable inkjet inks | AGFA NV (BE) | 2022-04-05 | — | — | US | disclosed |
| CN-108137974-B | UV curable inkjet inks | 爱克发印艺公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-108350295-B | UV curable inkjet inks | 爱克发有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-112320766-A | Preparation method and application of hollow mesoporous inorganic oxide nanosphere solid base | 西南大学 | 2021-02-05 | — | — | CN | disclosed |
| US-20200101102-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | IDERA PHARMACEUTICALS, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| EP-3156461-B1 | UV CURABLE INKJET INKS | AGFA NV (BE) | 2020-04-01 | — | — | EP | disclosed |
| US-10584258-B2 | UV curable inkjet inks | AGFA NV (BE) | 2020-03-10 | — | — | US | disclosed |
| US-10513620-B2 | UV curable inkjet inks | AGFA NV (BE) | 2019-12-24 | — | — | US | disclosed |
| US-20040020568-A1 | Non-toxic corrosion-protection conversion coats based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-02-05 | — | — | US | disclosed |
| US-20040016910-A1 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-01-29 | — | — | US | disclosed |
| US-20040011252-A1 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON | 2004-01-22 | — | — | US | disclosed |
| US-20030234063-A1 | Non-toxic corrosion-protection conversion coats based on cobalt | DAYTON, UNIVERSITY OF | 2003-12-25 | — | — | US | disclosed |
| US-20030230363-A1 | Non-toxic corrosion-protection rinses and seals based on cobalt | UNIVERSITY OF DAYTON | 2003-12-18 | — | — | US | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030035917-A1 | Image making medium | HYMAN SYDNEY (US) | 2003-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200101102-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | TLR9, TLR3, TLR7 | GPR35 211/4885ALDH1A1 4012/4885KDM4E 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.